Covaxin shows 100% efficacy against ‘severe Covid-19’, 78% overall


Bharat Biotech’s Covaxin has shown an overall efficacy of 78 per cent against Covid-19 and 100 per cent efficacy against a severe form of the disease, the vaccine maker said on Wednesday.

The vaccine has also shown 70 per cent efficacy against asymptomatic infections, suggesting that it prevents transmission. The second one interim analysis of Covaxin’s Phase 3 clinical trials is based on accruing 87 symptomatic cases of the virus.

Trials are double-blinded and the investigator and volunteer have no idea whether they’ve received a placebo or a vaccine shot. After a sure statistical number of cases of the disease are reported in the pattern, the data is un-blinded to see if those in the vaccinated arm got the disease.

“Because of the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against gentle, moderate, and severe Covid-19 disease. The efficacy against severe Covid-19 disease used to be 100 per cent, with an have an effect on on discount in hospitalisations. The efficacy against asymptomatic Covid-19 infection used to be 70 per cent, suggesting decreased transmission in recipients,” the Hyderabad based firm said.

In the first interim analysis, the whole virion (virus) inactivated Covid-19 vaccine candidate had shown an efficacy of 80.6 per cent. This included 2,433 people over the age of 60 and 4,500 people with co-morbidities.

The first interim analysis used to be based on 43 cases, of which 36 cases of Covid-19 were observed in the placebo group as opposed to 7 cases observed in the BBV152 (Covaxin) group, resulting in a point estimate of vaccine efficacy of 80.6 per cent.

The company is in process of ramping up its vaccine production capacity to 700 million doses yearly and may be pursuing approval for it in 60 countries. In Mexico, the Philippines, and Iran, it is already fetching $15-20 per shot.

The safety and efficacy results from the last analysis will be to be had in June and Bharat Biotech will submit the last outline to a peer-reviewed journal. Further, based on the achievement of the success criteria, placebo recipients have now grow to be eligible to get two doses of Covaxin.

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 10 per cent over the age of 60, with analysis conducted 14 days after the second one dose.

“Efficacy against SARS-Cov-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. Covaxin is now a global innovator vaccine derived from research and development from India. The efficacy data against severe Covid-19 and asymptomatic infections is highly remarkable, as this helps minimize hospitalizations and disease transmission, respectively,” said Bharat Biotech CMD Krishna Ella.

Commenting on the results, Balram Bhargava, secretary, Branch of Health Research and Director General of the Indian Council of Medical Research (which has collaborated with Bharat Biotech to develop the vaccine) said he used to be pleased with the results.

“The first indigenous vaccine has shown the efficacy of 78 per cent in the second one interim analysis. I am also happy to note that Covaxin works polite against most variants of SARS-CoV-2. These findings together consolidate the position of our indigenous vaccine in the global vaccine landscape,” said Bhargava.

Dear Reader,

Commerce Standard has at all times strived tough to supply up-to-date information and remark on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and fixed feedback on how to give a boost to our offering have only made our get to the bottom of and commitment to these ideals stronger. Even all the way through these difficult times arising out of Covid-19, we continue to remain dedicated to keeping you informed and up to date with credible news, authoritative views and incisive remark on topical issues of relevance.

We, then again, have a request.

As we battle the economic have an effect on of the pandemic, we need your toughen even more, in order that we will continue to provide you with more quality satisfied. Our subscription mannequin has seen an encouraging response from many of you, who have subscribed to our online satisfied. More subscription to our online satisfied can only help us achieve the goals of offering you even better and more applicable satisfied. We imagine in free, reasonable and credible journalism. Your toughen through more subscriptions can help us practise the journalism to which we are dedicated.

Reinforce quality journalism and subscribe to Commerce Standard.

Digital Editor

Top stories / News / Commerce


Please enter your comment!
Please enter your name here